Login to Your Account

Biomarin touts pipeline, reports Pompe data while awaiting Kyndrisa decision

By Jennifer Boggs
Managing Editor

Monday, January 11, 2016

SAN FRANCISCO – Though a decision on DMD drug Kyndrisa (drisapersen) is due any day now, Biomarin Pharmaceutical Inc. executives played down the U.S. market opportunity during their J.P. Morgan Healthcare Conference presentation, focusing instead on the market potential of the drug in Europe.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription